UNSPSC 51263119: Cicloprolol

This classification denotes a beta-adrenergic blocking agent with the molecular formula C18H29NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1K2ACH4U3R, chemically known as 2-propanol, 1-(4-(2-(cyclopropylmethoxy)ethoxy)phenoxy)-3-((1-methylethyl)amino)- but generally known as cicloprolol, which bears US NIH Compound Identifier 146294. European Medicines Agency schedules Cicloprolol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06248MIG.

UNSPSC 51263119 Cicloprolol is a Commodity code that captures pharmaceutical product procurement, though recent state and local solicitations under this code show activity in broader prescription and drug management rather than cicloprolol specifically. State and local governments buy naloxone, drug deactivation systems, and pharmacy benefit services through this taxonomy. Issuing bodies include county health departments and state health and human services commissions. Seminole County, Florida has posted a competitive IFB for naloxone and safe drug deactivation systems to support community health initiatives, while the Texas Health and Human Services Commission issued a Request for Information to evaluate direct-to-manufacturer prescription program capabilities. The scope spans both physical pharmaceutical products delivered on recurring schedules and strategic pharmacy benefit contracting to manage prescription costs and fulfillment efficiency.

Recent activity concentrates in Florida and Texas. Seminole County, Florida released IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, with a response deadline of July 26, 2023, and a two-year initial term plus one-year renewal option. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, to gather vendor capabilities on implementing direct-to-manufacturer prescription programs for self-insured employee health plans and state agencies, marking a shift toward strategic sourcing models outside traditional pharmacy benefit manager and group purchasing organization channels. Neither solicitation specifies set-aside designations for disadvantaged enterprises.